Mandate

Vinge has advised Vimian Group in connection with its rights issue

March 12, 2024

Vinge has advised Vimian Group AB (publ) in connection with a partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633 billion before deduction of transaction costs.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. At Vimian, one believes that every animal deserves the best available care. Vimian brings pioneering businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners.

Vinge’s team consisted of Dain Hård NevonenLinnéa Sellström, Anna Svensson, Michaela Ådén and Alexander Rüdén.

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024